GSK schließt drei-teilige Transaktion mit Novartis ab

– 4 Milliarden £ gehen an Shareholder zurück – Q1 Ergebnisse und Investor Meeting am 6.5.2015

GlaxoSmithKline plc (LSE/NYSE: GSK) gibt bekannt, dass die drei-teilige Transaktion mit Novartis heute abgeschlossen wurde. Als Ergebnis dieser Transaktion hat GSK das globale Impf-Business von Novartis (ausgenommen Influenza-Impfstoff)) für eine Gegenleistung von 5.25 Milliarden Dollar übernommen. Ein neues Consumer Healthcare Joint Venture mit Novartis wurde gegründet, an dem GSK einen mehrheitlichen Anteill von 63,5 % besitzt. Novartis erwarb gegen eine Leistung von insgesamt 16 Milliarden Dollar den Unternehmensbereich Onkologie von GSK.

Der Netto-Gewinn (nach Steuer) der Transaktion für GSK wird mit 7.8 Milliarden Dollar angenommen. Dieser Betrag beinhaltet auch die Zahlung von Novartis für das GSK Onkologie Portfolio von 16 Milliarden Dollar. Im Zuge der Transaktion müssen bis zu 1,5 Milliarden Dollar des Kaufpreises an Novartis zurückgehen, wenn bestimmte Voraussetzungen der COMBI-d Studie nicht erfüllt werden. Nach ersten positiven Ergebnissen dieser Studie am 6. Februar 2015 geht GSK davon aus, dass diese Vorgaben erfüllt werden können.

Als Ergebnis dieses heutigen Abschlusses plant GSK, die Einnahmen der Transaktion dazu zu verwenden, um den vollen angekündigten Kapitalertrag von 4 Milliarden £ an die Shareholder auszuzahlen. 
GSK plant am 6. Mai die ersten Quartalsergebnisse von 2015 zu veröffentlichen und ein Investor Meeting abzuhalten, im Zuge dessen die mittel- bzw. langfristigen Möglichkeiten der vergrößerten Unternehmensgruppe präsentiert werden.

Sir Andrew Witty, CEO, GSK sagt: “Der Abschluss dieser Transaktion ist ein großer Schritt in Richtung unserer Strategie, eine stärkere und ausgewogenere Plattform in unseren drei Kerngeschäften zu schaffen: Pharmazeutika, Consumer Healthcare und Impfstoffe. Wir werden nun auf eine schnelle Implementierung der Integrationspläne fokussieren, um das Wachstum und die Synergiemöglichkeiten, die wir im neuen Consumer Healthcare und Impfstoff-Business sehen, zu realisieren. Wir freuen uns darauf, mehr Einzelheiten und erste Ergebnisse mit unseren Shareholdern am 6. Mai zu teilen.”

Ansprechpartner: 
Prof. Dr. Siegfried Schön 
Director Medical & Regulatory
Tel. 01/970 75/200
siegfried.s.schoen@gsk.com 

Mag. Barbara Masser-Mayerl
Communications Manager, Corporate Affairs
Tel. 01/ 970 75 518
barbara.b.masser-mayerl@gsk.com

GlaxoSmithKline Pharma GmbH
Euro Plaza, Gebäude I, 4. Stock
Wagenseilgasse 3
1120 Wien
www.glaxosmithkline.at

Additional information 
Whilst completion of the transaction with Novartis has taken place today, there are certain jurisdictions in which the transfer of relevant assets to or by GSK will only take place following receipt of additional market-specific approvals or other matters relevant to those jurisdictions. The arrangements in relation to these jurisdictions are considered immaterial in the context of the transaction.

Terms defined in GSK's shareholder circular of 20 November 2014 have the same meaning where used in this announcement.

GSK enquiries:

UK Media enquiries:

David Mawdsley +44 (0) 20 8047 5502 (London)
Simon Steel +44 (0) 20 8047 5502 (London)
Sarah Spencer +44 (0) 20 8047 5502 (London)

US Media enquiries:

Stephen Rea +1 215 751 4394 (Philadelphia)
Sarah Alspach +1 202 715 1048 (Washington, DC)
Mary Anne Rhyne +1 919 483 0492 (North Carolina)

Analyst/Investor enquiries:

Ziba Shamsi +44 (0) 20 8047 5543 (London)
Tom Curry + 1 215 751 5419 (Philadelphia)
Gary Davies +44 (0) 20 8047 5503 (London)
James Dodwell +44 (0) 20 8047 2406 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Information regarding forward-looking statements
This announcement includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “plans”, “projects”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include, but are not limited to, statements regarding GSK’s intentions, beliefs or current expectations concerning, among other things, GSK’s business, results of operations, financial position, prospects, growth, strategies and the industry in which it operates as well as those of the Novartis businesses that are the subject of the transaction. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward-looking statements are not guarantees of future performance and the actual results of GSK’s operations and financial position, and the development of the markets and the industry in which GSK operates, may differ materially from those described in, or suggested by, the forward-looking statements contained in this announcement. The same applies in respect of the Novartis Businesses that are the subject of the transaction. In addition, even if the results of operations, financial position and the development of the markets and the industry in which GSK operates are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements including, without limitation, general economic and business conditions, industry trends, competition, changes in regulation, currency fluctuations, changes in its business strategy, political and economic uncertainty and other factors discussed in this announcement.

Forward-looking statements may, and often do, differ materially from actual results. Any forward-looking statements in this announcement speak only as of their respective dates, reflect GSK’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to GSK’s operations, results of operations and growth strategy. You should specifically consider the factors identified in this document, in addition to the risk factors that may affect GSK’s operations which are described under “Risk Factors” in the Company’s 2014 Annual Report on Form 20-F, which could cause actual results to differ before making any decision in relation to the Transaction as well as those of the Novartis businesses that are the subject of the transaction. Subject to the requirements of the FCA, the London Stock Exchange, the Listing Rules and the Disclosure and Transparency Rules (and/or any regulatory requirements) or applicable law, GSK explicitly disclaims any obligation or undertaking publicly to release the result of any revisions to any forward-looking statements in this announcement that may occur due to any change in GSK’s expectations or to reflect events or circumstances after the date of this announcement.